ClinicalTrials.gg
Status unknownNCT01982461Updated Nov 13, 2013

A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Hypercholesterolemia.

An interventional study of Rosuvastatin and Crestor® in Hypercholesterolemia, sponsored by Pin Siang Medical Biotechnology Co., Ltd.. Status unknown at 1 site in Taiwan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2013-11-13.

Sponsored by Pin Siang Medical Biotechnology Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Nov 2013), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
20 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 59 studies testing rosuvastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. rosuvastatin · Hypercholesterolemia.

Planned enrollment
50th of 57
40 · median 203
Started
2013
with 4 others
No phase
3 of 59
none open now
Registered
42nd of 59
by date

Among the 59 studies testing rosuvastatin in Hypercholesterolemia, this one is the 50th largest by planned enrollment of the 57 interventional ones that give a count, is one of 5 that started in 2013, is one of 3 with no phase, and was the 42nd registered.

Hypercholesterolemia

1,180 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

None of the 59 studies testing rosuvastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 58 Hypercholesterolemia studies recruiting now, 25 (43%) set no upper age limit and 21 (36%) stop at 75 or younger; 10 take children under 18; 12 take healthy volunteers.

This study: 20 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 59 studies testing rosuvastatin in Hypercholesterolemia as a file.
02

Study summary

The objective of this trial is to assess the efficacy of reducing plasma low-density lipoprotein(LDL) cholesterol and safety in two different brand drugs, Roty F.C. Tablets 10mg and Crestor 10mg F.C. Tablets in hypercholesterolemia population.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 20 to 85;
  • LDL - C between 130 mg/dL and 250 mg/dL;
  • TG \< 400 mg/dL;
  • Who without use of any statin within 2 week prior to the trial;
  • given.

Exclusion criteria

Exclusion Criteria:

  • Known or history of SAE with another HMG-CoA reductase inhibitor, in particular any history of myopathy;
  • Active liver disease/severe hepatic impairment( C,ALT2×);
  • Treatment with Cyclosporin or any disallowed drug;
  • Patients with unstable angina pectoris;
  • Pregnant, lactating women;
  • Patients who have severe medical condition(s) that in the view of the Investigator prohibits participation in the trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Rosuvastatin

    One Rosuvastatin tablet 10mg taken once daily.

    Drug: Rosuvastatin

  • Active comparator
    Crestor®

    One Crestor® tablet 10mg taken once daily.

    Drug: Crestor®

Interventions

06

What researchers measure

Primary outcomes

  1. The primary efficacy variable will be defined as the percent mean change in LDL-C from baseline to 12 weeks.

    Time frame: baseline to week 12

Secondary outcomes

  1. The secondary efficacy variable will be described as the change of plasma AGE, sRAGE, Gas6 and sAx1.

    Time frame: baseline to week 12

07

Study locations

1 of 1 sites recruiting
  • Tri-Service General Hospital
    Taipei, 11490, Taiwan
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013 and a primary completion of Jan 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2013
First posted
Nov 13, 2013
Start
Nov 2013
Primary completionEst.
Jan 2014
Last update
Nov 13, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01982461
Lead sponsor
Pin Siang Medical Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Nov 13, 2013
Start date
Nov 2013
Primary completion
Jan 2014 (estimated)
Last update
Nov 13, 2013

Study contacts

Lu-Hsin Lu, M.S.
Contact
flora@twtungda.com.tw
886-2-26270255 ext. 206
Yi-Jen Hung, M.D.
principal investigator · Tri-Service General Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion